Bosakitug Biosimilar - Research Grade

Human

TSLP

>1mg/ml

IgG1 - kappa

CHO Cells

Tezepelumab Biosimilar - Research Grade (ICH5213), Ecleralimab Biosimilar - Research Grade (ICH5499), Ocankitug Biosimilar - Research Grade (ICH5720)

https://www.imgt.org/mAb-DB/

ICH3002

Q969D9

Blue ice

This product is a research-grade biosimilar of bosakitug, supplied as an unconjugated, non-therapeutic analog of the originator anti-TSLP antibody for research use only. It is not the clinical drug and is not intended for diagnostic or therapeutic application. Bosakitug (also known as ATI-045) is an investigational humanized IgG1 monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), a human epithelial-derived cytokine that sits near the apex of the type 2 inflammatory cascade. It has been developed as a high-affinity, high-potency neutralizing antibody with a slow dissociation rate and extended residence time, and is under clinical investigation in allergic and inflammatory conditions such as atopic dermatitis and asthma. This biosimilar reagent reproduces the binding specificity of the originator against human TSLP and is offered in ichor.bio's in-vivo research format: low endotoxin, high purity, and available at bulk milligram-to-gram scale. It is intended for functional and comparative studies where a well-characterized, cost-effective anti-TSLP binder is required, rather than as a substitute for the approved or investigational therapeutic. Format is IgG1 with a kappa light chain. TSLP (thymic stromal lymphopoietin; UniProt Q969D9) is an IL-7-related cytokine produced mainly by epithelial cells at barrier surfaces, including skin keratinocytes, airway epithelium, and gut. It signals through a heterodimeric receptor comprising the TSLP receptor chain (TSLPR/CRLF2) together with the interleukin-7 receptor alpha chain (IL-7Ra), activating JAK/STAT5 signaling. TSLP acts as an alarmin at the top of the type 2 inflammatory cascade: it conditions dendritic cells to drive naive CD4+ T cells toward a Th2 phenotype and promotes downstream release of IL-4, IL-5, and IL-13, recruiting eosinophils, basophils, and mast cells. It also contributes to neutrophilic inflammation via other pathways. Genetic variation at the TSLP locus and elevated TSLP expression in asthmatic airways and atopic dermatitis lesions implicate it in allergic disease, making it an attractive upstream therapeutic and research target.

Thymic stromal lymphopoietin

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Bosakitug biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Bosakitug biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Bosakitug biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Bosakitug that binds TSLP; for research use only.